⚡ Flash Summary
Glaxo Pakistan’s Corporate Briefing Session for 2025 reveals a positive financial outlook. Net sales increased to 45 billion (from 44 billion in 2024). The gross margin significantly improved to 36% (from 22% in 2024), showcasing enhanced profitability. The profit before tax (PBT) grew to 10 billion (from 6 billion in 2024), and earnings per share (EPS) rose to 19.57 (from 11.25 in 2024), indicating strong financial performance.
Signal: BUY 📈
Strength: 8/10
Sentiment: POSITIVE
Time Horizon: MEDIUM_TERM
📌 Key Takeaways
- 📈 Net Sales Increased: Reached 45 billion (2024: 44 billion)
- 💰 Gross Margin Expansion: Improved to 36% (2024: 22%)
- 📊 PBT Growth: Increased to 10 billion (2024: 6 billion)
- 💸 EPS Growth: Rose to 19.57 (2024: 11.25)
- 🌱 Return on Equity: 21% (2024: 14%)
- 💼 Current Ratio: Improved to 1.88 (2024: 1.68)
- 🗓️ Inventory Days: Increased to 164 days (2024: 125 days)
- 🧾 Receivable Days: Stable at 4 days
- 💸 Payable Days: Decreased to 52 days (2024: 66 days)
- 🏆 Top Employer: Recognized as a Top Employer in Pakistan for five consecutive years
- 🌏 Single Digit Inflation: Achieved single digit inflation throughout the year.
- 📉 Interest Rate Decline: Experienced an 11% decline in interest rates over the past year.
- GDP Growth: FY 2025 GDP growth reported at 2.7%.
- Exchange Rate Stability: Exchange rate remained stable during the year.
- KSE-100 Index: KSE-100 index is at an all-time high.
🎯 Investment Thesis
Based on the strong financial performance, improved profitability, and positive growth metrics, a BUY recommendation is justified. The company has demonstrated its ability to increase sales and improve efficiency, leading to significant profit growth. The price target, based on a conservative P/E ratio, is 293.55. The time horizon is medium-term, with an expectation of continued growth and value creation.
View Original PDF
Disclaimer: AI-generated analysis. Not financial advice.
